ClearPoint Neuro Unveils Robotic Neuro-Navigation System to Advance Cell and Gene Therapy Delivery
Reuters
Oct 02
ClearPoint Neuro Unveils Robotic Neuro-Navigation System to Advance Cell and Gene Therapy Delivery
ClearPoint Neuro Inc. has announced the development and demonstration of its proprietary Robotic Neuro-Navigation System, designed to enhance precision and flexibility in minimally invasive cranial surgical procedures such as cell and gene therapy infusions, laser catheter placement, biopsies, and deep brain stimulation. The company will present a prototype of this innovative robotic system at the upcoming 75th Annual Congress of Neurological Surgeons $(CNS)$ in Los Angeles, scheduled for October 13th-15th. The new system integrates ClearPoint's neuro navigation software with the KUKA LBR Med Robotic Arm, aiming to provide consistent and flexible support for the commercial launch of various cell and gene therapies. The product is currently in the development stage and has not yet been submitted to any regulatory body.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1080952) on October 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.